Moscardo Elena, Maurin Anne, Dorigatti Roberto, Champeroux Pascal, Richard Serge
Safety Pharmacology, Safety Assessment Department, GlaxoSmithKline R&D Centre, Via Fleming 4, VERONA (37135), Italy.
J Pharmacol Toxicol Methods. 2007 Sep-Oct;56(2):239-55. doi: 10.1016/j.vascn.2007.03.007. Epub 2007 May 24.
The most widely used test to identify undesired effects of drugs on the central and the peripheral nervous system is the neurobehavioural observation battery adapted from that first described by Irwin in mice. As a neurobehavioural assessment is based on observations; thus, all factors involved need to be controlled and standardised to make the data collected objective, reproducible, reliable and predictive of safety liabilities.
An observation battery comprising 58 signs with assigned full details of numerical scores was defined, and a standard design with associated recording, presenting and analysing data system was established. Validation studies were conducted with chlorpromazine, amphetamine, diazepam or clonidine given orally to rats or mice, in order to assess if this methodology could clearly differentiate the profile of effects produced by these compounds. The analysis of data from 80 control rats allowed for the assessment of the normal behaviour in order to characterise the inter-individual, daytime-related variability and the habituation of animals to the procedure.
The reference compounds induced their typical and expected transient effects on neurobehaviour, observed both in the home cage and open-arena, and on body temperature. In particular, amphetamine induced a stimulation of the nervous system activities and marked hyperthermia. Chlorpromazine, diazepam and clonidine induced depressive, anxiolytic or sedative effects associated with hypothermia. The analysis of data collected in control animals allowed for the identification of 6 signs which scored differently from the assigned normality at the first handling occasion due to the characteristic fear reactions to the unknown, and 9 signs at 8 h post-dose due to the animal's habituation to experimental conditions and handling.
The neurobehavioural changes expected by reference compounds administration were detected. These results confirm that by using this methodology the normal behaviour of the rat and the mouse, the daytime-related variability and the habituation of animals can be characterised, allowing a refined, reliable and reproducible neurobehavioural assessment of test substances in rodents.
用于识别药物对中枢神经系统和外周神经系统不良影响的最广泛使用的测试是基于欧文最初在小鼠中描述的方法改编而来的神经行为观察组合测试。由于神经行为评估基于观察,因此,所有相关因素都需要得到控制和标准化,以使收集到的数据具有客观性、可重复性、可靠性,并能预测安全性问题。
定义了一个包含58个体征并配有详细数值评分的观察组合测试,并建立了一个相关的记录、呈现和分析数据的标准系统。对大鼠或小鼠口服氯丙嗪、苯丙胺、地西泮或可乐定进行验证研究,以评估该方法是否能清晰区分这些化合物产生的效应特征。对80只对照大鼠的数据进行分析,以评估正常行为,从而确定个体间、日间相关的变异性以及动物对该程序的适应性。
参比化合物对神经行为产生了典型且预期的短暂影响,在饲养笼和旷场中以及体温方面均有观察到。特别是,苯丙胺刺激了神经系统活动并导致明显的体温过高。氯丙嗪、地西泮和可乐定分别产生了与体温过低相关的抑郁、抗焦虑或镇静作用。对对照动物收集的数据进行分析后发现,有6个体征在首次处理时因对未知的特征性恐惧反应而得分与指定的正常情况不同,还有9个体征在给药后8小时因动物对实验条件和处理的适应性而得分不同。
检测到了参比化合物给药后预期的神经行为变化。这些结果证实,通过使用该方法,可以确定大鼠和小鼠的正常行为、日间相关变异性以及动物的适应性,从而对啮齿动物中的受试物质进行精确、可靠且可重复的神经行为评估。